185 related articles for article (PubMed ID: 37903971)
1. Integrated analysis of histone lysine lactylation (Kla)-specific genes suggests that NR6A1, OSBP2 and UNC119B are novel therapeutic targets for hepatocellular carcinoma.
Wu Q; Li X; Long M; Xie X; Liu Q
Sci Rep; 2023 Oct; 13(1):18642. PubMed ID: 37903971
[TBL] [Abstract][Full Text] [Related]
2. Lysine lactylation (Kla) might be a novel therapeutic target for breast cancer.
Deng J; Liao X
BMC Med Genomics; 2023 Nov; 16(1):283. PubMed ID: 37950222
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis and validation of SNX7 as a novel biomarker for the diagnosis, prognosis, and prediction of chemotherapy and immunotherapy response in hepatocellular carcinoma.
Chen J; Gao G; Zhang Y; Dai P; Huang Y
BMC Cancer; 2023 Sep; 23(1):899. PubMed ID: 37743471
[TBL] [Abstract][Full Text] [Related]
4. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a Prognostic Model for Hepatocellular Carcinoma Based on Bioinformatics and the Role of NR6A1 in the Progression of HCC.
Lin ZH; Zhang J; Zhuang LK; Xin YN; Xuan SY
J Clin Transl Hepatol; 2022 Oct; 10(5):901-912. PubMed ID: 36304495
[TBL] [Abstract][Full Text] [Related]
6. Establishment and Evaluation of Exosomes-Related Gene Risk Model in Hepatocellular Carcinoma.
Zhu L; Lou Y; Xiao Q; Wang L; Chen G; Yang W; Wang T
Biochem Genet; 2024 Apr; 62(2):698-717. PubMed ID: 37405532
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel histone phosphorylation prognostic signature in hepatocellular carcinoma based on bulk and single-cell RNA sequencing.
Fan L; Xu L; Tian S; Zheng X
Front Endocrinol (Lausanne); 2022; 13():965445. PubMed ID: 36120466
[TBL] [Abstract][Full Text] [Related]
8. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
9. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma.
Zhang X; Zhuge J; Liu J; Xia Z; Wang H; Gao Q; Jiang H; Qu Y; Fan L; Ma J; Tan C; Luo W; Luo Y
Front Immunol; 2023; 14():1153423. PubMed ID: 37006285
[TBL] [Abstract][Full Text] [Related]
10. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
11. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma.
Tang B; Zhang X; Yang X; Wang W; Li R; Liu Y
Front Immunol; 2022; 13():1013248. PubMed ID: 36466855
[TBL] [Abstract][Full Text] [Related]
12. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
13. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis.
Xiao H; Wang B; Xiong HX; Guan JF; Wang J; Tan T; Lin K; Zou SB; Hu ZG; Wang K
J Cell Physiol; 2021 Apr; 236(4):2572-2591. PubMed ID: 32853412
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma.
Wang Z; Zhu J; Liu Y; Liu C; Wang W; Chen F; Ma L
J Transl Med; 2020 Feb; 18(1):67. PubMed ID: 32046766
[TBL] [Abstract][Full Text] [Related]
15. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
16. Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma.
Yang Z; Yan C; Ma J; Peng P; Ren X; Cai S; Shen X; Wu Y; Zhang S; Wang X; Qiu S; Zhou J; Fan J; Huang H; Gao Q
Nat Metab; 2023 Jan; 5(1):61-79. PubMed ID: 36593272
[TBL] [Abstract][Full Text] [Related]
17. A novel prognostic model based on immunogenic cell death-related genes for improved risk stratification in hepatocellular carcinoma patients.
Liu T; Chen X; Peng B; Liang C; Zhang H; Wang S
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10255-10267. PubMed ID: 37269346
[TBL] [Abstract][Full Text] [Related]
18. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma.
Wang Z; Pan L; Guo D; Luo X; Tang J; Yang W; Zhang Y; Luo A; Gu Y; Pan Y
Cancer Med; 2021 Jun; 10(11):3808-3821. PubMed ID: 33934539
[TBL] [Abstract][Full Text] [Related]
19. Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
Xu L; Zheng Q; Liu W
BMC Cancer; 2022 Mar; 22(1):229. PubMed ID: 35236323
[TBL] [Abstract][Full Text] [Related]
20. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
Yan Z; He M; He L; Wei L; Zhang Y
Front Immunol; 2021; 12():723271. PubMed ID: 34925311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]